Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical

Introduction

Abstract

This report provides a comprehensive review of 27 candidate therapeutic antibodies and 42 candidate vaccines that are being evaluated for the treatment of lung cancer, covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 targets, while the vaccines are directed at 24 antigens or antigen combinations.

Globally, lung cancer is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.

Patient needs and the high burden of lung cancer are driving the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing strategies, are urgently required. Today, advances continue to be made in drug treatments for lung cancer; in chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy, in the development of new therapeutic antibodies and therapeutic vaccines.

This report provides a comprehensive review of lung cancer immunotherapy. With a focus on therapeutic vaccines and antibodies, it reviews R&D and clinical developments in the treatment of lung cancer as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers. It provides a comprehensive review of pipeline developments, therapeutic strategies and clinical findings, covering therapeutic vaccines and antibodies.

Today, around 70 immunotherapies are being developed or evaluated for the treatment of lung cancer. This report reviews developments on 27 candidate therapeutic antibodies and 42 candidate vaccines for treating lung cancer, most of which are in clinical development.

The lung cancer immunotherapy pipeline is showing substantial innovation and many new strategies are being evaluated. Today' s pipeline of therapeutic antibodies are directed at 17 drug targets. On the vaccine front, 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting vaccines have been treated as single targeting strategies.

More than 90% of the immunotherapy candidates in development or being evaluated for treating lung cancer that are identified in this report, are in clinical development. This report gives an overview of the status and clinical findings of these candidate therapies. It also gives developmental and market-related perspectives in this rapidly developing field.

• Late-stage (Phases 2/3, 3 and Approved, n = 4) therapeutic antibodies and companies
• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) therapeutic antibodies and companies
• Late-stage (Phases 2/3, 3 and Approved, n = 5) vaccines and companies
• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) vaccines and companies
• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting lung cancer, Phases 1, 1/2 and 2
• Drug targets against which therapeutic antibodies are being directed, from preclinical through to Phase 3, and Approved
• Antigen/antigen combinations being targeted by vaccines, from preclinical through to Phase 3, and Approved
• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phases 1-3) of therapeutic antibodies and vaccines being evaluated for the treatment of lung cancer
• Summaries of the clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses), following clinical trials (Phases 1-3) of therapeutic antibodies being evaluated for the treatment of lung cancer
• Summaries of the clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses), following clinical trials (Phases 1-3) of vaccines being evaluated for the treatment of lung cancer
• Commercial partnerships and collaborations on pipeline therapeutic antibodies and vaccines
• Drug combination strategies in the evaluation of therapeutic antibodies and vaccines for targeting of lung cancer
• A comprehensive listing of salient details of clinical trials of therapeutic antibodies and vaccines being evaluated for the treatment of lung cancer
• Technical and market insights and perspectives in the development and clinical evaluation of therapeutic antibodies and vaccines for the treatment of lung cancer
• Competitive and market-related information

Table of Contents

Table of Contents

Executive Summary

Chapter 1 - Background

• Summary

• 1. Lung Cancer
  • 1.1. Statistics
  • 1.2. Diagnosis
  • 1.3. Lung Cancer Staging
  • 1.4. Treatment of Lung Cancer
  • 1.5. Survival Rates
  • 1.6. Cost of Lung Cancer
  • 1.7. New Developments
  • 1.8. This Report

Chapter 2 - Approved and Late-Stage Therapeutic Antibodies

• Summary
  • 2.1. Introduction
  • 2.2. Overview
  • 2.3. (One antibody, Approved)
  • 2.4. - 2.6 (Three antibodies, Phase 3)

• References

Chapter 3 - Approved and Late-Stage Vaccines

• Summary
  • 3.1. Introduction
  • 3.2. Overview
  • 3.3. (One vaccine, Approved)
  • 3.4. - 3.6 (Three vaccines, Phase 3)
  • 3.7. (One vaccine, Phase 2/3)

• References

Chapter 4 - Early-Stage Therapeutic Antibodies

• Summary
  • 4.1. Introduction
  • 4.2. Overview
  • 4.3. - 4.12. (Ten antibodies, Phase 2)
  • 4.13. - 4.18. (Six antibodies, Phase 1/2)
  • 4.19. - 4.23. (Five antibodies, Phase 1)
  • 4.24. - 4.25. (Two Antibodies, Preclinical)

• References

Chapter 5 - Early-Stage Vaccines

• Summary
  • 5.1. Introduction
  • 5.2. Overview
  • 5.3. - 5.12. (Ten vaccines, Phase 2)
  • 5.13. - 5.22. (Ten vaccines, Phase 1/2)
  • 5.23. - 5.37. (Fifteen vaccines, Phase 1)
  • 5.38. - 5.39. (Two vaccines, Preclinical)

• References

Chapter 6 - Other Candidate Therapies

• Summary
  • 6.1. Introduction
  • 6.2. Overview
  • 6.3. (One Immune Activator, Phase 2)
  • 6.4. (One Antibody Conjugate, Phase 1/2)
  • 6.5. (One Bispecific Antibody, Phase 1)
  • 6.6. (One Antibody Conjugate, Phase 1)
  • 6.7. (One Immune Stimulant, Phase 1)
  • 6.8. (One Antibody Conjugate, Phase 1)

• References

Chapter 7 - Discussion

• 7.1. Background
• 7.2. Pipeline
• 7.3. Therapeutic Antibodies
• 7.4. Vaccines
• 7.5. Other Candidate Therapies
• 7.6. Companies
• 7.7. Therapeutic Targets
• 7.8. Therapeutic Approaches
• 7.9. Conditions
• 7.10. Market Perspectives

• References

Tables

• 1.1. Global incidence and mortality from lung cancer, 2008
• 1.2. NSCLC survival rates, according to cancer stage
• 1.3a. Five-year relative cancer survival rates in the USA, for white males
• 1.3b. Five-year relative cancer survival rates in the USA for white females
• 1.4. US national expenditure on different cancers (2006).
• 1.5. US lost productivity due to different cancer types in the US, 2005
• 2.1. Approved/late-stage candidate therapeutic antibodies for the treatment of lung cancer
• 3.1. Approved/late-stage vaccines for the treatment of lung cancer
• 4.1. Early-stage therapeutic antibodies being developed or evaluated for the treatment of lung cancer or for lung cancer/other cancers
• 5.1. Early-stage vaccines being developed or evaluated for the treatment of lung cancer or lung cancer/other cancers
• 6.1. Other (largely antibody-related) therapies being developed or evaluated for the treatment of lung cancer or lung cancer/other cancers
• 7.1. Approved/late-stage therapeutic antibodies being developed for the treatment of lung cancer
• 7.2. Early-stage candidate therapeutic antibodies being developed or evaluated for the treatment of lung cancer or for lung cancer/other cancers
• 7.3. Approved/late-stage candidate vaccines being developed for the treatment of lung cancer
• 7.4. Early-stage candidate vaccines being developed or evaluated for lung cancer or for lung/other cancers

• Other (primarily antibody-related) therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
• Approved/candidate therapeutic antibodies for the treatment of lung cancer or for lung cancer/other cancers
• Approved/candidate vaccines for the treatment of lung cancer or for lung cancer/other cancers
• Other candidate therapies (primarily antibody-related) for the treatment of lung cancer or for lung cancer/other cancers.
• NSCLC survival rates, according to cancer stage

Figures

• 4.1. Early-staged pipeline therapeutic antibodies for the treatment of lung cancer or lung cancer/other cancers
• 5.1. Early-staged pipeline vaccines for the treatment of lung cancer or lung cancer/other cancers
• 7.1. Approved and pipeline therapeutic antibodies, vaccines and other (primarily antibody-based) therapies being developed or evaluated for the treatment of lung cancer or for lung cancer/other cancers
• 7.2. Approved and pipeline therapeutic antibodies and vaccines being developed or evaluated for the treatment of lung cancer or for lung cancer/other cancers
• 7.3. Late and early-stage therapeutic antibodies, vaccines and other (primarily antibody-based) therapies being developed or evaluated for the treatment of lung cancer or for lung cancer/other cancers
• 7.4. Approved and pipeline therapeutic antibodies being developed or evaluated for the treatment of lung cancer or for lung/other cancers
• 7.5. Early-stage pipeline vaccines in development or being evaluated for lung cancer or for lung/other cancers
• 7.6. Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for lung cancer or for lung cancer/other cancers
• 7.7. Organisations engaged in the development or evaluation of therapeutic antibodies, therapeutic vaccines and other therapies for lung cancer or lung cancer/other cancers
• 7.8. Countries of organisations engaged in the development/evaluation of therapeutic antibodies, therapeutic vaccines and other therapies for lung cancer or lung cancer/other cancers
• 7.9. Geographic regions of organisations engaged in the development or evaluation of therapeutic antibodies, therapeutic vaccines and other therapies for lung cancer or lung cancer/other cancers
• 7.10. Organisations developing or evaluating lung cancer therapeutic antibodies
• 7.11. Organisations developing or evaluating lung cancer therapeutic vaccines
• 7.12. Clinical trials of therapeutic antibodies for the treatment of lung cancer or lung cancer/other cancers, involving single or combination agents.
• 7.13. Clinical trials of vaccines for the treatment of lung cancer or lung cancer/other cancers, involving single or combination agents

Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical published by BioPharm Reports (Technology and Markets Ltd) in October 1, 2011. This report consists of 186 Pages and the price starts from US $ 2384.